165 related articles for article (PubMed ID: 30656384)
21. Flagellin Encoded in Gene-Based Vector Vaccines Is a Route-Dependent Immune Adjuvant.
Rady HF; Dai G; Huang W; Shellito JE; Ramsay AJ
PLoS One; 2016; 11(2):e0148701. PubMed ID: 26844553
[TBL] [Abstract][Full Text] [Related]
22. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
23. Targeting cryptic epitope with modified antigen coupled to the surface of liposomes induces strong antitumor CD8 T-cell immune responses in vivo.
Horiuchi Y; Takagi A; Uchida T; Akatsuka T
Oncol Rep; 2015 Dec; 34(6):2827-36. PubMed ID: 26398429
[TBL] [Abstract][Full Text] [Related]
24. Enhanced induction of telomerase-specific CD4(+) T cells using dendritic cells transfected with RNA encoding a chimeric gene product.
Su Z; Vieweg J; Weizer AZ; Dahm P; Yancey D; Turaga V; Higgins J; Boczkowski D; Gilboa E; Dannull J
Cancer Res; 2002 Sep; 62(17):5041-8. PubMed ID: 12208759
[TBL] [Abstract][Full Text] [Related]
25. Prime-boost immunization with DNA vaccine: mucosal route of administration changes the rules.
Eo SK; Gierynska M; Kamar AA; Rouse BT
J Immunol; 2001 May; 166(9):5473-9. PubMed ID: 11313385
[TBL] [Abstract][Full Text] [Related]
26. Mucosal Priming with a Recombinant Influenza A Virus-Vectored Vaccine Elicits T-Cell and Antibody Responses to HIV-1 in Mice.
Wang J; Shu T; Deng W; Zheng Y; Liao M; Ye X; Han L; He P; Zheng X; Li T; Feng Y; Hu F; Li P; Sun C; Chen L; Li F; Feng L
J Virol; 2021 May; 95(12):. PubMed ID: 33789991
[TBL] [Abstract][Full Text] [Related]
27. Lentivector prime and vaccinia virus vector boost generate high-quality CD8 memory T cells and prevent autochthonous mouse melanoma.
Xiao H; Peng Y; Hong Y; Liu Y; Guo ZS; Bartlett DL; Fu N; He Y
J Immunol; 2011 Aug; 187(4):1788-96. PubMed ID: 21746967
[TBL] [Abstract][Full Text] [Related]
28. Measles Vaccines Designed for Enhanced CD8
Busch E; Kubon KD; Mayer JKM; Pidelaserra-Martí G; Albert J; Hoyler B; Heidbuechel JPW; Stephenson KB; Lichty BD; Osen W; Eichmüller SB; Jäger D; Ungerechts G; Engeland CE
Viruses; 2020 Feb; 12(2):. PubMed ID: 32098134
[TBL] [Abstract][Full Text] [Related]
29. A molecularly cloned Schwarz strain of measles virus vaccine induces strong immune responses in macaques and transgenic mice.
Combredet C; Labrousse V; Mollet L; Lorin C; Delebecque F; Hurtrel B; McClure H; Feinberg MB; Brahic M; Tangy F
J Virol; 2003 Nov; 77(21):11546-54. PubMed ID: 14557640
[TBL] [Abstract][Full Text] [Related]
30. Diepitope multiple antigen peptide of hTERT trigger stronger anti-tumor immune responses in vitro.
Liao ZL; Luo G; Xie X; Tang XD; Bai JY; Guo H; Yang SM
Int Immunopharmacol; 2013 Aug; 16(4):444-50. PubMed ID: 23714071
[TBL] [Abstract][Full Text] [Related]
31. Induction of CD8+ T cells to an HIV-1 antigen through a prime boost regimen with heterologous E1-deleted adenoviral vaccine carriers.
Pinto AR; Fitzgerald JC; Giles-Davis W; Gao GP; Wilson JM; Ertl HC
J Immunol; 2003 Dec; 171(12):6774-9. PubMed ID: 14662882
[TBL] [Abstract][Full Text] [Related]
32. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses.
Hodge JW; McLaughlin JP; Kantor JA; Schlom J
Vaccine; 1997; 15(6-7):759-68. PubMed ID: 9178479
[TBL] [Abstract][Full Text] [Related]
33. Interleukin-12 (IL-12) enhancement of the cellular immune response against human immunodeficiency virus type 1 env antigen in a DNA prime/vaccinia virus boost vaccine regimen is time and dose dependent: suppressive effects of IL-12 boost are mediated by nitric oxide.
Gherardi MM; Ramírez JC; Esteban M
J Virol; 2000 Jul; 74(14):6278-86. PubMed ID: 10864637
[TBL] [Abstract][Full Text] [Related]
34. Preventive vaccination with telomerase controls tumor growth in genetically engineered and carcinogen-induced mouse models of cancer.
Mennuni C; Ugel S; Mori F; Cipriani B; Iezzi M; Pannellini T; Lazzaro D; Ciliberto G; La Monica N; Zanovello P; Bronte V; Scarselli E
Cancer Res; 2008 Dec; 68(23):9865-74. PubMed ID: 19047167
[TBL] [Abstract][Full Text] [Related]
35. Immunogenic HLA-B*0702-restricted epitopes derived from human telomerase reverse transcriptase that elicit antitumor cytotoxic T-cell responses.
Adotévi O; Mollier K; Neuveut C; Cardinaud S; Boulanger E; Mignen B; Fridman WH; Zanetti M; Charneau P; Tartour E; Lemonnier F; Langlade-Demoyen P
Clin Cancer Res; 2006 May; 12(10):3158-67. PubMed ID: 16707616
[TBL] [Abstract][Full Text] [Related]
36. Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost.
Asbach B; Kibler KV; Köstler J; Perdiguero B; Yates NL; Stanfield-Oakley S; Tomaras GD; Kao SF; Foulds KE; Roederer M; Seaman MS; Montefiori DC; Parks R; Ferrari G; Forthal DN; Phogat S; Tartaglia J; Barnett SW; Self SG; Gottardo R; Cristillo AD; Weiss DE; Galmin L; Ding S; Heeney JL; Esteban M; Jacobs BL; Pantaleo G; Wagner R
J Virol; 2019 Feb; 93(3):. PubMed ID: 30429343
[TBL] [Abstract][Full Text] [Related]
37. Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant.
Kolibab K; Yang A; Derrick SC; Waldmann TA; Perera LP; Morris SL
Clin Vaccine Immunol; 2010 May; 17(5):793-801. PubMed ID: 20357059
[TBL] [Abstract][Full Text] [Related]
38. Enhanced antitumor effect against human telomerase reverse transcriptase (hTERT) by vaccination with chemotactic-hTERT gene-modified tumor cell and the combination with anti-4-1BB monoclonal antibodies.
Lin X; Zhou C; Wang S; Wang D; Ma W; Liang X; Lin C; Wang Z; Li J; Guo S; Zhang Y; Zhang S
Int J Cancer; 2006 Oct; 119(8):1886-96. PubMed ID: 16708388
[TBL] [Abstract][Full Text] [Related]
39. Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies.
Garber DA; O'Mara LA; Zhao J; Gangadhara S; An I; Feinberg MB
PLoS One; 2009; 4(5):e5445. PubMed ID: 19421328
[TBL] [Abstract][Full Text] [Related]
40. Intradermal NKT cell activation during DNA priming in heterologous prime-boost vaccination enhances T cell responses and protection against Leishmania.
Dondji B; Deak E; Goldsmith-Pestana K; Perez-Jimenez E; Esteban M; Miyake S; Yamamura T; McMahon-Pratt D
Eur J Immunol; 2008 Mar; 38(3):706-19. PubMed ID: 18286565
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]